DexCom (DXCM)
(Delayed Data from NSDQ)
$118.77 USD
+0.37 (0.31%)
Updated May 31, 2024 04:00 PM ET
After-Market: $118.96 +0.19 (0.16%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$118.77 USD
+0.37 (0.31%)
Updated May 31, 2024 04:00 PM ET
After-Market: $118.96 +0.19 (0.16%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Zacks News
DexCom (DXCM) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, DexCom (DXCM) closed at $355.02, marking a -0.27% move from the previous day.
DexCom (DXCM) Gains As Market Dips: What You Should Know
by Zacks Equity Research
DexCom (DXCM) closed at $358.57 in the latest trading session, marking a +0.18% move from the prior day.
Zacks Industry Outlook Highlights: Teladoc, PRA Health and DexCom
by Zacks Equity Research
Zacks Industry Outlook Highlights: Teladoc, PRA Health and DexCom
IoMT Meets New Healthcare Needs: 3 MedTech Trends to Watch
by Urmimala Biswas
Medical device which has for long taken tiny steps toward IoMT is now going all out to make the most of the advancements in this space amid the pandemic.
DexCom (DXCM) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
DexCom's (DXCM) third-quarter results benefit from solid segmental performance.
DexCom (DXCM) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
DexCom (DXCM) delivered earnings and revenue surprises of 46.88% and 4.96%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
DexCom (DXCM) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
DexCom (DXCM) closed at $387.84 in the latest trading session, marking a -1.17% move from the prior day.
DexCom (DXCM) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) third-quarter results are likely to reflect rising global awareness of its real-time CGM.
DexCom (DXCM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
DexCom (DXCM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will DexCom (DXCM) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
DexCom (DXCM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
DexCom (DXCM) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
DexCom (DXCM) closed the most recent trading day at $394.01, moving -1.73% from the previous trading session.
DexCom (DXCM) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, DexCom (DXCM) closed at $387.50, marking a -1.6% move from the previous day.
DexCom (DXCM) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, DexCom (DXCM) closed at $413.84, marking a +0.39% move from the previous day.
4 Best Diabetes Device Stocks to Focus on Amid Coronavirus Crisis
by Debanjana Dey
Here are a few diabetes-centric MedTech stocks that investors can focus on to reap profits amid the pandemic-battered stock market situation.
DexCom (DXCM) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, DexCom (DXCM) closed at $389.31, marking a +0.8% move from the previous day.
DexCom Introduces Registry to Monitor Outcomes of G6 System
by Zacks Equity Research
DexCom (DXCM) sets up registry to track outcomes of patients and healthcare professionals using CGM in hospitals.
DexCom (DXCM) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
DexCom (DXCM) closed the most recent trading day at $383.46, moving -1.68% from the previous trading session.
Should iShares Morningstar MidCap Growth ETF (JKH) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JKH
DexCom (DXCM) Down 0.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
DexCom (DXCM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should iShares Morningstar MidCap Growth ETF (JKH) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JKH
10 Best-Performing Stocks in Nasdaq ETF as Index Tops 11,000
by Sweta Killa
The latest broad market rally has pushed the tech-heavy Nasdaq Composite Index to new record highs above the 11,000 milestone.
DexCom (DXCM) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
DexCom's (DXCM) second-quarter results benefit from solid segmental performance.
DexCom (DXCM) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
DexCom (DXCM) delivered earnings and revenue surprises of 154.84% and 11.11%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Why DexCom (DXCM) Might Surprise This Earnings Season
by Zacks Equity Research
DexCom (DXCM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
DexCom (DXCM) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) second-quarter results are likely to reflect rising global awareness of its real-time CGM.